Specifically, setanaxib has been described to replicate the beneficial effects seen in multiple NOX1/4 KO models of liver fibrosis, reducing oxidative stress, hepatocyte apoptosis, inflammation and fibrosis in different types of CLD, including NASH, bile duct ligation and CCl4 treatment [88,90]. The gene discussed is NOX1; the disease is Hepatic fibrosis.